Sanofi

Sanofi plans to buy assets from U.S. biopharmaceutical company Inhibrx in a deal valued at up to $2.2 billion. Sanofi plans to buy assets from U.S. biopharmaceutical company Inhibrx in a deal valued at up to $2.2 billion. FOLLOW US ON GOOGLE NEWS Read original article here Denial of responsibility! Techno Blender is an automatic aggregator of the all world’s media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors.…

A RSV-infected child receives treatment, as RS-Virus infections spread among children at Missio children's clinic Moenchberg, in Wuerzburg, Germany, December 2, 2022. Heiko Becker | ReutersThe Centers for Disease Control and Prevention expedited the release of more than 77,000 additional doses of a new drug designed to protect infants from respiratory syncytial virus amid an ongoing shortage of the treatment in the U.S.The CDC's move late Thursday to increase the availability of Beyfortus, a monoclonal antibody from…

A doctor is injecting a vaccine to a baby boyKarl Tapales | Moment | Getty ImagesSanofi expects its infant RSV shot to roll out in the U.S. before respiratory virus season this fall, a company spokesperson said Friday.The Food and Drug Administration on Monday approved Beyfortus, a monoclonal antibody that is administered as a single dose to infants before or during their first respiratory syncytial virus season.The Sanofi spokesperson said the company does not expect any challenges with manufacturing or capacity to meet…

Blood sample for respiratory syncytial virus (RSV) testJarun011 | Istock | Getty ImagesThe Food and Drug Administration on Monday approved AstraZeneca and Sanofi's shot that protects infants and toddlers against respiratory syncytial virus, which is the leading cause of hospitalization among babies in the U.S.Nirsevimab is the first shot approved by the FDA to protect all infants against RSV regardless of whether they are healthy or have a medical condition.related investing newsThe FDA approval of nirsevimab comes…

HealthJustices rule unanimously that Amgen patents relating to its cholesterol drug Repatha shouldn’t have been granted HealthJustices rule unanimously that Amgen patents relating to its cholesterol drug Repatha shouldn’t have been granted FOLLOW US ON GOOGLE NEWS Read original article here Denial of responsibility! Techno Blender is an automatic aggregator of the all world’s media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials…

Eli Lilly CEO Dave Ricks on Wednesday promised not to raise prices on the company's insulin products again — the only executive to do so before a Senate Health Committee hearing on making the life-saving diabetes drug more affordable.Sen. Bernie Sanders, the committee's chair, asked Ricks and the CEOs of Novo Nordisk and Sanofi to commit to "never increase the price of any insulin drug again." The three companies control over 90% of the global insulin market. Ricks was the only executive who outright agreed to Sanders'…

French drugmaker Sanofi SA said it would cut the price of some of its insulin products by as much as 78% in the U.S., joining other big pharmaceutical companies facing pressure to reduce the cost of diabetes treatments.Sanofi plans to take a 78% list-price reduction on Lantus, the company’s most widely used insulin in the U.S., and a 70% cut on its Apidra product starting in January 2024, the company said Thursday.  Sanofi also said it would cap a Lantus patient’s monthly out-of-pocket cost…

Sen. Bernie Sander’s new bill will cap drug prices to what Eli Lilly’s Humalog cost when it was first released in 1996.Photo: Spencer Platt (Getty Images)On Thursday, Vermont Sen. Bernie Sanders and a gaggle of Democrats introduced a new bill that would cap insulin drug prices to just $20 per vial no matter which company is making it.The bill, called the Insulin for All Act of 2023, caps the price at what the major pharmaceutical company Eli Lilly originally setfor a month’s supply of its insulin treatment Humalog back…

A U.S. appeals court ruled that pharmaceutical companies can limit their shipments of federally-discounted drugs to pharmacies, in a major win for the drugmakers and a blow to hospitals and clinics that receive the low-priced medicines. The ruling on Monday, by a three-judge panel of the Philadelphia-based Third Circuit Court of Appeals, was in favor of drugmakers Sanofi SA, SNY 0.33% AstraZeneca AZN 0.33%…

A 3D illustration of the Respiratory syncytial virus (RSV), Illustration: Shutterstock (Shutterstock)We’re getting ever closer to besting a frequent microscopic source of misery: the respiratory syncytial virus. Late Tuesday, Moderna announced the seemingly successful Phase III trial results of its experimental RSV vaccine. In older adults, the vaccine appeared to be over 80% effective at preventing two or more symptoms linked to lower respiratory infections caused by the virus.RSV is a common cause of respiratory…